Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Ophthalmology | Genetic Disease
Macular Degeneration Clinical Trials
A listing of Macular Degeneration medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (24) clinical trials
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
This is a multicenter, randomized, double-masked, parallel group, placebo-controlled study evaluating the effects of ALK-001 administered daily by mouth in subjects with Stargardt disease (ABCA4-related). Stargardt disease is a rare genetic disorder that leads to damage to the retina and results in legal blindness. The onset of symptoms usually occurs ...
IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD
128 subjects will be enrolled in the trial and randomized in a 1:1 ratio to receive either IAI every three months for 24 months or sham injections. Enrollment will be stratified in order to ensure a balance between the two treatment groups for subjects who were diagnosed with exudative AMD ...
Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Part 1: Approximately 66 subjects will be randomized in a 1:1:1 ratio to the following dose groups Zimura Dose Administration 1 Zimura Dose Administration 2 Sham Administration 1 Part 2: Approximately 135 subjects will be randomized in a 1:2:2 ratio to the following dose groups Zimura Dose Administration 3 Zimura ...
Treatment of Patients With Neovascular AMD Using Indocyanine Green-Mediated Photothrombosis (i-MP).
Comparative, controlled, multicenter, masked, randomized study, three parallel groups, comparing the Indocyanine Green-Mediated Photothrombosis to two control groups, for the treatment of neovascular Age-Related Macular Degeneration. Only patients matching the following criteria are eligible: A. BCVA worse than 20/80 and neovascular complex with some component of occult CNV as defined ...
Intravitreal Bevacizumab for Age-Related Macular Degeneration
The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious ...
Bevacizumab and Photodynamic Therapy in Neovascular Age Related Macular Degeneration
The neovascular age related macular degeneration(AMD) is a important cause of legal blindness in adults older than 50 years. Currently the treatment is photodynamic therapy that offer stabilization and limited visual improvement after 2 years of therapy. Bevacizumab has been reported effective used as intravenous injection for AMD. But serious ...
Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-Related Macular Degeneration
This phase II study was designed to evaluate the safety, tolerability, and efficacy of bevacizumab treatment in conjunction with PDT at the low fluence rate compared with bevacizumab alone or combined with PDT at the standard fluence rate, in patients with all types of choroidal neovascularization secondary to AMD. Hypothesis: ...
Assessment of Psychological Strain and Perioperative Fear in Intravitreal Injections
The aim of the study is to assess the influence of perioperative factors on objective outcome measures, which indicate the physiologic stress reaction.
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
Ascertain the long term safety and efficacy of ziv-aflibercept in a large variety of ocular diseases and over a long-term after its proven safety and efficacy in the laboratory, in phase one study and in isolated case report. Background and Significance: Anti-VEGF therapy is currently one of the mainstay of ...
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration
Objective: Age-related macular degeneration (AMD), the leading cause of blindness in people over age 65 in the United States, is a heterogeneous clinical entity in which retinal degeneration occurs predominantly in the macula in the context of aging and leads to impairment of central visual acuity (VA). AMD occurs in ...